Frequency and features of non-alcoholic fatty liver disease/ steatohepatitis in patients with inflammatory bowel disease
Abstract
The factors associated with non-alcoholic fatty liver disease/steatohepatitis in patients with ulcerative colitis (UC) and Crohn’s disease (CD) were studied. A high incidence of non-alcoholic fatty liver disease/steatohepatitis was revealed in patients with inflammatory bowel disease (IBD). In patients with IBD, non-alcoholic fatty liver disease was associated with age and the presence of metabolic risk factors, as well as high disease activity. In patients with CD, an association of non-alcoholic fatty liver disease with the extraintestinal manifestations of the basic disease was observed. In patients with CD without metabolic risk factors, non-alcoholic fatty liver disease was associated with hospitalization rates. The presence of Epstein — Barr virus and cytomegalovirus in the mucous membrane of the large intestine is not associated with non-alcoholic fatty liver disease/steatohepatitis.
About the Authors
Ya. A. Krasner
Novosibirsk State Medical University
Russian Federation
Russian Federation
Krasner Yakov Arkadyevich — Assistant of the Department of Propaedautics of Internal Diseases.
52, Krasny Prospect, Novosibirsk, 630091
M. F. Osipenko
Novosibirsk State Medical University
Russian Federation
Russian Federation
Osipenko Marina Fedorovna — Dr. Sci. (Med.), Professor, Head of the Department of Propaedautics of Internal Diseases
E. Yu. Valuyskikh
State Scientific-Research Institute of Physiology and Basic Medicine
Russian Federation
Russian Federation
Valuyskikh Ekaterina Yuryevna — Cand. Sci. (Med.), Head of the Therapeutic Department.
Novosibirsk
M. V. Rezakova
State Scientific-Research Institute of Physiology and Basic Medicine
Russian Federation
Russian Federation
Rezakova Mariya Viktorovna — Cand. Sci. (Med.), Head of the Radiology Department.
Novosibirsk
K. A. Babich
Novosibirsk State University
Russian Federation
Russian Federation
Babich Ksenya Arkadyevna — 6th-year Student
References
1. Gizard E., Ford A.C., Bronowicki J.P., Peyrin-Biroulet L. (2014). Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 40 (1), 3-15.
2. Chao C.Y., Battat R., Khoury A.A. et al. (2016). Coexistence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J. Gastroenterol, 22 (34), 7727-7734.
3. Palumbo C.S., Restellini S., Chao C.Y. et al. (2019). Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: A cohort study using transient elastography. Inflam. Bowel Dis., 25 (1), 124-133.
4. Fousekis F.S., Theopistos V.I., Katsanos K.H., Tsianos E.V., Christodoulou D.K. (2018). Hepatobiliary manifestations and complications in inflammatory bowel diseases: A review. Gastroenterol. Res., 11 (2), 8394.
5. Ivashkin V.T., Shelygin Yu.A., Khalif I.L. et al. (2017). Clinical recommendations of the Russian Association of Gastroenterology and the Russian Association of Coloproctology for the diagnostics and treatment of ulcerative colitis. Coloproctology, 1, 6-30. In Russ.
6. Ivashkin V.T., Shelygin Yu.A., Khalif I.L. et al. (2017). Clinical guide of Russian Association of Gastroenterology and Russian Association of Coloproctology on diagnostics and treatment of Crohn’s disease. Colo-proctology, 2, 7-29. In Russ.
7. Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S. et al. (2016). Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Russ. J. of Gastroenterology, Hepatology and Coloproctology, 26 (2), 24-42.
8. Wai C.T., Greenson J.K., Fontana R.J. et al. (2003). A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 38, 518-526.
9. Vallet-Pichard A., Mallet V., Nalpas B. et al. (2007). FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology, 46, 32-36.
10. Principi M., Iannone A., Losurdo G. et al. (2018). Nonalcoholic fatty liver disease in inflammatory bowel disease: prevalence and risk factors. Inflamm. Bowel Dis., 24 (7), 1589-1596.
11. Sourianarayanane A., Garg G., Smith T.H. et al. (2013). Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J. Crohn’s Colitis, 7 (8), 279-285.
12. Carr R.M., Patel A., Bownik H. et al. (2017). Intestinal inflammation does not predict nonalcoholic fatty liver disease severity in inflammatory bowel disease patients. Dig. Dis. Sci., 62 (5), 1354-1361.
13. Marchesini G., Day Ch.P., Dufour J.F. et al. (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388-1402.
14. Cheng H.Y., Wang H.Y., Chang W.H. et al. (2013). Nonalcoholic fatty liver disease: Prevalence, influence on age and sex, and relationship with metabolic syndrome and insulin resistance. Int. J. Gerontol., 7 (4), 194-198.
15. Sartini A., Gitto S., Bianchini M. et al. (2018). Nonalcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis., 9, 87.
16. Charriere G., Cousin B., Arnaud E. et al. (2003). Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem., 278 (11), 9850-9855.
17. Desreumaux P., Geboes K., Gambiez L. et al. (1998). Has the mesenteric tissue an inflammatory role in Crohn’s disease? Digestion, 59 (3), 751-757.
18. Schaffler A., Herfarth H. (2005). Creeping fat in Crohn’s disease: travelling in a creeper lane of research? Gut., 54 (6), 742-744.
19. Goh E.C., Jeong Y.Y., Donghee K. et al. (2016). Associations between white blood cell count and the development of incidental nonalcoholic fatty liver disease. Gastroenterol. Res. Pract, 2016.
20. Ilchenko L.Yu., Nikitin I.G. (2018). Hyperammonium in patients with pre-cirrhosis stage: clinical reality? Russ. Archives of Internal Medicine, 8 (3), 186-193. In Russ.
Review
For citations:
Krasner Ya.A., Osipenko M.F., Valuyskikh E.Yu., Rezakova M.V., Babich K.A. Frequency and features of non-alcoholic fatty liver disease/ steatohepatitis in patients with inflammatory bowel disease. Journal of Siberian Medical Sciences. 2019;(3):63-73.
Views:
287
Email this article 